Receive our newsletter – data, insights and analysis delivered to you
  1. Research Reports
November 24, 2016

Report: Psoriatic arthritis market to reach $12.6bn by 2025

The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by GlobalData.

The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by GlobalData.

Titled 'PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025', the report forecasts the psoriatic arthritis market to witness a compound annual growth rate of 10.74%.

An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth. Educational campaigns and an interdisciplinary approach to managing the condition have increased awareness of the disease.

As a result, the total number of treated cases in the 7MM is expected to increase from roughly 770,000 in 2015 to 1.2 million by 2025, according to GlobalData immunology analyst Alexandra Annis, MS.

"An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth."

Existing treatment options do not have long-term efficacy requiring patients to have a cycle through the drugs. New therapeutic options with strong clinical efficacy will provide patients and physicians with more choice.

The recent approval of Novartis’ IL-17 inhibitor Cosentyx has been welcomed by the psoriatic arthritis community. The drug shows the highest clinical efficacy of any biologic approved with X-ray assessment data demonstrating 84% of patients as showing no progression in structural joint damage over a period of two years of use.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly’s Taltz (ixekizumab), AstraZeneca’s Lumicef (brodalumab) and Celgene’s oral therapy Otezla (apremilast).

Lumicef and Taltz are expected to emerge as the leading drugs in the market, with the latter expected to gross an estimated $1.42bn in total sales by 2025. New entrants, however, are expected to face difficulties in terms of increased choice and reduced drug costs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU